The conditional approval of fanregratinib is supported by pivotal phase 2 data showing a 42.5% objective response rate in pretreated FGFR2-altered intrahepatic cholangiocarcinoma.
Commentary|Videos|August 12, 2024
Small Clones, Outsized Consequences: The Many Faces of Clonal Hematopoiesis
Author(s)Danielle E. Hammond, MD, FRCP(C)
Danielle E. Hammond, MD, FRCP(C), of The University of Texas MD Anderson Cancer Center, discusses the many faces of clonal hematopoiesis.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
2
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
3
Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS
4
DISC-3405 Reduces Phlebotomy Events and Controls Hematocrit in Polycythemia Vera
5